MX2019012749A - Metodos para tratar trastornos pediatricos. - Google Patents

Metodos para tratar trastornos pediatricos.

Info

Publication number
MX2019012749A
MX2019012749A MX2019012749A MX2019012749A MX2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A
Authority
MX
Mexico
Prior art keywords
vedolizumab
integrin
beta
alpha
antibodies specific
Prior art date
Application number
MX2019012749A
Other languages
English (en)
Inventor
Rosario Maria
A Shetzline Michael
R Treem William
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MX2019012749A publication Critical patent/MX2019012749A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

La invención proporciona métodos para el tratamiento de pacientes pediátricos con enfermedad intestinal inflamatoria mediante el uso de vedolizumab.
MX2019012749A 2017-04-28 2018-04-26 Metodos para tratar trastornos pediatricos. MX2019012749A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492031P 2017-04-28 2017-04-28
PCT/US2018/029579 WO2018200818A2 (en) 2017-04-28 2018-04-26 Method of treating pediatric disorders

Publications (1)

Publication Number Publication Date
MX2019012749A true MX2019012749A (es) 2020-02-03

Family

ID=62455814

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012749A MX2019012749A (es) 2017-04-28 2018-04-26 Metodos para tratar trastornos pediatricos.

Country Status (12)

Country Link
US (1) US20200179486A1 (es)
EP (1) EP3615071A2 (es)
JP (2) JP2020517671A (es)
KR (1) KR20190141148A (es)
CN (1) CN110612120A (es)
AR (1) AR111491A1 (es)
AU (1) AU2018256840A1 (es)
BR (1) BR112019022268A2 (es)
CA (1) CA3061320A1 (es)
MX (1) MX2019012749A (es)
TW (2) TW202342102A (es)
WO (1) WO2018200818A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
MX9706049A (es) 1995-02-10 1998-02-28 Leukosite Inc Adresinas vasculares mucosas y sus usos.
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
WO2003099773A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
CN101077867B (zh) 2002-11-18 2012-10-10 坎莫森特里克斯公司 芳基磺酰胺
RS57636B1 (sr) 2004-09-03 2018-11-30 Genentech Inc Humanizovani anti-beta7 antagonisti i njihova upotreba
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
WO2010107752A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
AU2016222683A1 (en) * 2015-02-26 2017-07-13 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
BR112018068625A2 (pt) * 2016-03-14 2019-07-30 Millennium Pharm Inc métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro

Also Published As

Publication number Publication date
TW201842932A (zh) 2018-12-16
BR112019022268A2 (pt) 2020-05-19
WO2018200818A9 (en) 2019-01-17
US20200179486A1 (en) 2020-06-11
CN110612120A (zh) 2019-12-24
CA3061320A1 (en) 2018-11-01
TW202342102A (zh) 2023-11-01
JP2023113655A (ja) 2023-08-16
TWI811216B (zh) 2023-08-11
RU2019138312A (ru) 2021-05-28
WO2018200818A3 (en) 2018-12-06
AU2018256840A1 (en) 2019-11-07
JP2020517671A (ja) 2020-06-18
RU2019138312A3 (es) 2022-02-03
EP3615071A2 (en) 2020-03-04
AR111491A1 (es) 2019-07-17
WO2018200818A2 (en) 2018-11-01
KR20190141148A (ko) 2019-12-23

Similar Documents

Publication Publication Date Title
HRP20181796T1 (hr) Derivati naftiridina kao antagonisti alfa v beta 6 integrina, namijenjeni liječenju, primjerice, fibrotičnih bolesti
MY188940A (en) Anti-pd-l1 antibodies and diagnostic uses thereof
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
IL277217A (en) Use of anti-IL-36R antibodies to treat inflammatory bowel disease
IL279260A (en) KDM1A inhibitors for the treatment of diseases
MX2019013693A (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteinas de las mismas.
SG10201809411PA (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
MX2023003519A (es) Anticuerpo anti-semaforina 4d humano.
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
SG11202107978RA (en) Methods and system for the reconstruction of drug response and disease networks and uses thereof
IL276896A (en) Methods for treating Crohn's disease with a specific anti-IL23 antibody
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
EP3585818A4 (en) ANTI-HLA-DQ2.5 / 8 ANTIBODIES AND ITS USE FOR THE TREATMENT OF C LIATIC DISEASE
GB201804724D0 (en) Method of diagnosing cceliac disease
MX2019012749A (es) Metodos para tratar trastornos pediatricos.
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof
GB201808575D0 (en) Methods for the treatment of psoriatic arthrits
MX2019010060A (es) Composiciones y metodo para tratar cancer.
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
MX2017010306A (es) Bloqueadores del receptor de la hormona del crecimiento en la prevencion y tratamiento de enfermedades.
MA41090A (fr) Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
IL274536A (en) Methods for prognosis or treatment of parkinson's disease
GB201911728D0 (en) Bacterial composistions for the treatment of disease
SG11202106912WA (en) Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases